The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

The decision had been expected by April 1, but the agency now says it needs more information before moving forward.

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

The FDA delays full approval for Novavax's COVID-19 vaccine, citing the need for additional data. Read more here.

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

It reported revenues of 38.41 million yuan in the first half of 2024 and a net loss of 903 million yuan, hit by falling ...

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...